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ABSTRACT 
Background: Tuberculosis is a worldwide problem particularly in developing countries. 
Different clinical outcomes,  such as the asymptomatic phase during infection or the 
symptomatic stage during active disease leads to activation and expansion of cellular immune 
responses in order to control the infection. This process of latency and active TB infection is 
a highly dynamic interaction between the host and the immunogenicity of M.tb. The detailed 
antigen specific analysis of the M.tb host response will likely lead to a better understanding of 
the pathogenesis of TB in human subjects and may help to identify markers of immune 
protection. There is a need to develop an effective TB vaccine and biomarkers of protection. 
Currently, different TB vaccine candidates contain M.tb components that are able to induce T 
cell activation and subsequent IFN-Ȗ release. For instance, TB10.4 is such a novel vaccine 
candidate, it is highly immunogenic and present in M.tb and in the BCG vaccine strain. We 
characterized immune recognition patterns from Honduran patients with TB with a 
particularly focus on TB10.4 in order to better understand the infection biology, heterologous 
immune responses and the role of memory T cell formation.   
Aims: i) Defining and comparing M.tb specific immune responses in individuals with active 
and latent tuberculosis infection using cell based immune assays and a panel of specific M.tb 
target antigens ii) Characterization of the recognition pattern of the humoral and cellular 
responses towards TB10.4 (Rv0288) and iii) Studying the relationship between molecular 
mimicry and tuberculosis using TB10.4 as a paradigm.  
Methodology: We selected a clinically well-defined population in order to perform cell-
based immune assays (i.e Interferon gamma release assay), microarray peptide technology, 
and a bioplex assay, to gauge immune responses against a panel of recombinant or synthetic 
M.tb target antigens. 
Results and discussion: Paper I: This work represents the first analysis of cellular immune 
responses directed against M.tb associated targets in individuals from Honduras and provides 
a robust concept for identification of TB targets; we were able to identify differential target 
recognition patterns in TB+ patients vs TB exposed health care workers. Comprehensive 
pattern recognition analysis using biologically relevant targets revealed that enzymes 
involved in M.tb lipid synthesis serve as targets for T cells, defined by IFN-Ȗ and IL-17 
production. Paper II: We mapped humoral and cellular immune responses against the 
TB10.4 protein in non-human primates (NHPs) as well as in TB patients from Honduras. 
Immune responses in NHP were very focused, in contrast toTB10.4 directed immune 
responses in humans. We postulated that cross recognition of closely related antigens could 
be one possible explanation. The report shows substantial differences in cellular recognition 
comparing NHP and human immune responses. This T cell responses may be sustained via 
cross reactive immune responses recognizing the TB10.4 target and non-M.tb related target 
antigens. 
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1 EPIDEMIOLOGY OF TUBERCULOSIS, CHAPTER 1 
 
1.1 GLOBAL AND REGIONAL FACTS OF TUBERCULOSIS 
 
Tuberculosis (TB) is an increasing threat worldwide contributing to morbidity and 
mortality among young adults, caused by Mycobacterium tuberculosis (M.tb).  
Pulmonary tuberculosis is an aerosol infection and represents the most prevalent form of 
the disease; this contagious airborne form implies a global public health problem. 1.3 
million people succumb to TB, including 320,000 individuals with HIV infections and two 
billion people living with Latent TB infection (LTBI). The incidence is 137 cases per 100,000 
with therapy outcome that reaches 86% [1] , if M.tb is susceptible to antibiotic treatment.  
Nowadays,  the global challenge is to develop new strategies of treatment and diagnostics 
for preventing the multidrug resistance (MDR-TB) and extensively Drug resistance (XDR-
TB) form of TB that fail to respond to first and second line of anti TB therapy. Therefore, a 
global plan to stop TB, attributed to prioritize 22 High Burden Countries (HBC) that 
represent 80% of TB cases around the world, counting 35% alone for India and China [2-3] 
was developed.  
The region of America is one of the WHO’ six regions with a TB incidence of 29/100000, a 
prevalence of 37/100000, showing 82% of treatment success; 41% of patients with TB 
tested HIV-positive. The Americas include only one HBC-Brazil and the regional plan 2006-
2015 attributed Brazil 35% of the cases in the Region followed by Peru (15%)[3].  
In Central America the highest rate of TB during 2012 correspond to Guatemala, followed 
by Honduras with an incidence of 60 and 54/100,000 respectively[4-5].    
During 2012,  3,014 new and relapsed cases of tuberculosis were detected in Honduras;  
2816/3014 TB patients were HIV-positive[5]. HIV remains a serious public health problem 
increasing the risk factor for progression to active disease. 1.8% patients with TB 
experience MDR-TB[5], they fail to limit the active form of the disease and fail to respond 
to first and second line drugs.  
The ability to contain TB latency worldwide can be maintained during life time unless host 
immunity or environmental factors compromise such a status.  HIV co-infection, 
malnutrition, crowds, aging, stress, type 2 diabetes mellitus, use of immunosuppressive 
agents and genetic factors may contribute to progression of TB infection. Yet, other 
factors from the pathogen, may also play a role:  latency reflects the transition from 
replicating to no replicating dormant bacilli, this transition is influenced by diverse factors, 
including oxygen deprivation and nitric oxide formation.  
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To control TB expansion, nations have developed political commitment and strategies 
promoting actions for prevention, developing diagnostics, novel drug therapy and 
monitoring TB instruments to gauge the TB epidemic.   
In Honduras, the health care system is comprised by the  Ministry of Health, Social 
Security Institute (IHSS) and the Private 
Sector; all of them providing assistance 
in tuberculosis services.  Public service 
includes 6 National Hospitals; at the 
intermediate level 20 Health Regions, 6 
Regional Hospitals, 16 Areas Hospitals; 
and the local level  252 CESAMO, 1058 
CESAR and 4 CLIPER (smaller and 
peripheral health centers). Among 
primary tuberculosis care institutions is 
the National TB Control Program (NTP) 
[6] which  was established in 1957 with 
strategies to control TB in Honduras and 
to develop pilot activities using Directly 
Observed Therapy, Short-Course (DOTS) 
in 1998; by 2003, the NTP reported 100 
percent DOTS coverage[7] and achieved 
a treatment success rate of 86 percent, 
a marked improvement from 75 
percent in 1998. 
Honduras has incorporated the vaccine Bacille Calmette-Guerin (BCG) in the National 
Vaccination Program since 1977 in 298 districts in the country,  with an increasing 
coverage range from 25% (1980), 55% (1985), 97%(1995), to 99% in 2008. The BCG 
vaccination is of obligatory use in newborns in the National Health System; yet, the 
protection of the vaccine is limited to meningitis in childhood, yet seems not to be 
protective against pulmonary TB[8]. Therefore, a novel vaccine is a priority for TB control 
and challenges the goal to reduce the global incidence of active tuberculosis. 
 
 
 
 
 
Box 1. Honduras General and Health Facts 
 
Capital City       Tegucigalpa 
Population  8,296,693 
Official languages Spanish 
Total Area sq km 112,492 
GDP (PPP)/per capita $ 3830 
Expenditure on health, % GDP    7.3 
Life expectancy at birth m/f 67/73 years 
People living with HIV/AIDS 39,000 
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Figure1. Estimated tuberculosis incidence rates by country, 2012[5]. Global tuberculosis 
report 2013. WHO 2013. 
 
22 TB high burden countries: Afghanistan, Bangladesh, Brazil, Cambodia, China, the 
Democratic Republic of the Congo, Ethiopia, India, Indonesia, Kenya, Mozambique, 
Myanmar, Nigeria, Pakistan, The Philippines, the Russian Federation, South Africa, 
Thailand, Uganda, the United Republic of Tanzania, Vietnam and Zimbabwe. Combined, 
India and China account for an estimated 35% of the world’s cases of TB. 
 
Figure 2. Geographical distribution of tuberculosis in Honduras, all forms at intermediate 
level in 20 Health Regions. 2010. 
 
 Secretaria de Salud, Programa Nacional de la Tuberculosis, Dr. Marvin Maldonado 
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2 PATHOGENESIS AND IMMUNITY OF TUBERCULOSIS, 
CHAPTER 2 
 
Tuberculosis is a chronic infection acquired by the inhalation of infected particles from a 
patients with active TB. Small drops of 1-3 µ can reach the alveolar area containing 
approximately three bacilli per particle. However, it is not known what the minimal 
infectious dose of TB for humans is. Different numbers of bacilli may be required to 
establish infection, depending on the genetic background of the populations, regions, 
different M.tb strains, virulence, bacterial load, and the host immune response.  
The exposition to M.tb and the M.tb directed host response display different clinical 
outcomes: i) asymptomatic: during infection-sterilization or latent TB infection (LTBI); ii) 
symptomatic phase during active disease manifestation. Most of the individuals are able 
to develop an effective cell mediated immune response to control the infectious stage, 
while 10% of exposed individuals do experience immune protection during their lifetime 
and may develop clinical disease either as primary infection or reactivation.   
Once bacilli are ingested, alveolar macrophages engulf M.tb, they are  deposited in the 
lung parenchyma,  while macrophages others migrate through the blood stream to 
draining lymph nodes (DLN),  where they encounter Dendritic cells (DC) for priming T-cells.   
Since M.tb is an intracellular bacterium that resides within the compartments of 
macrophages, presentation of specific mycobacterial antigens by Major Histocompatibility 
Complex (MHC) is needed to activate effector T lymphocytes, both CD4+ and CD8+ T-cells, 
and generate an inflammatory response orchestrated by cytokines and chemokines.   
 
2.1 EARLY LINES OF DEFENSE 
 
The nature of protective immune response against M.tb it is not completely understood. 
Most likely, it reflects an active interaction between the immune competences of the host 
the virulence of the pathogen. 
The initial defense against TB are macrophages, they play role as target cells of M.tb. They   
represents also a first line defense and stimulate pro-inflammatory cytokines. The 
interaction between M.tb and macrophages is mediated by different sets of molecules, 
e.g.  FcR, complement receptors (CR1, CR3, CR4), mannose receptors, surfactant protein 
receptors, CD14 and scavenger receptors[9].  After bacterias are engulfed, a chain of 
events starts, i.e. phagosome-lysosome fusion, generation of reactive oxygen 
intermediates, and generation of reactive nitrogen intermediates, particularly nitric oxide. 
Some of these events are actively inhibited by M.tb and represent immune evasion 
mechanisms.  Simultaneously, T lymphocytes may be recruited to the macrophage and 
further stimulate it in order to inhibit M.tb growth or to kill mycobacteria.  
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Macrophages can also produce IL-12 to amplify this pathway.  Dendritic cells- DCs are 
professional Antigen Presenting Cells (APCs) and are present in the lung tissue on the 
onset of inflammatory immune response as immature DC. Upon M.tb infection in the lung, 
DCs become activated through Toll like receptor signals. After antigen recognition, uptake 
and antigen internalization, DCs become mature and migrate to peripheral lymph nodes. 
During the migration and maturation process, DC may express surface markers, adhesion 
molecules, co-stimulatory molecules (CD80, CD86) accompanied of increased synthesis of 
MHC class I and II molecules.  In the protective immune responses, DCs are believed to 
induce maturation of T cells towards a Th1 profile.  
Neutrophils- PMNs are professional phagocytes with microbicidal effects, they produce 
chemokines (e.g. IP-10, MCP-1, MIP-1aB) and pro-inflammatory cytokines (e.g. TNF-ɲͿŝŶ
response to microbial pattern recognition receptors. They are believed to contribute in 
the first line of defense against TB[10]. This situation may also represent a double-edged 
sword, if neutrophils lead to exacerbated inflammation in the lung, evoking pathology and 
tissue damage. 
Toll Like Receptors (TLR) - Their role is still controversial in immune response of TB. TLR-
dependent activation of the NF-kB pathway is critical in infectious and inflammatory 
disease processes mediating cytokine activation signal transduction. This pathway is 
mediated via the adapter protein MyD88, which links to TLR signaling cascades, but also to 
IL-1B and IL-18 (IL-1BR, IL-18R). TLR signals promote production of microbicidal effectors 
molecules, such as ROI, RNI and microbicidal peptides (e.g. defensins). In a mouse model, 
TLR2 confers responsiveness to LAM, while heat killed M.tb elicit TLR-2 dependent 
responses, promoting the production of IL-2 and inducible nitric oxide synthase (iNOS). 
Therefore, distinct mycobacterial components can interact with different members of the 
TLR family. 
Natural Killer cells (NK) - They are granular lymphocytes of the innate immune system 
that participate in allograft rejection and killing of transformed and viral-infected cells. In 
addition to their (perforin/granzyme- or Fas ligand-mediated) cytotoxic effector functions, 
NK cells produce pro-inflammatory cytokines, most prominently IFN-ɶ͘,ƵŵĂŶE<ĐĞůůƐĂƌĞ
known to directly lyse M.tb infected monocytes and macrophages in vitro; but they also 
actively restrict mycobacterial growth in an apoptosis-dependent but Fas/FasL 
independent manner. Killing can be further enhanced by addition of IL-2, IL-12 and 
glutathione. NK cells are capable of mounting a vigorous response to M.tb, their exact 
function in vivo remains enigmatic[10]. 
 
2.2 ACQUIRED IMMUNITY: CELLULAR AND HUMORAL RESPONSES 
 
The antigen specific, adaptive immune response execute several effectors functions via 
the activation of components of the innate immune system[11]. Early lines of defense and 
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adaptive immune response ensue, with the generation of antigen-specific effector cells 
that target the specific pathogen, as well as memory T-cells that can prevent re-infection - 
or control a latent TB infection. 
Antigen specific immune responses can be differentiated into i) cell mediated mechanisms 
which include T-cell activation and effector mechanisms and ii) humoral immune 
responses consisting in B cell maturation and antibody production.  In immune responses 
directed against M.tb, the role of B and T cell responses are not mutually exclusive. Once 
the bacilli activate dendritic cells, they will stimulate T lymphocytes, which in turn provide 
help to B cells and orchestrate adaptive immune response. T cells target and promote 
apoptotic killing of pathogen-infected cells either directly or through cytokine activation of 
neighboring immune cells. B cells may produce antibodies that neutralize invasion and 
target infectious agents for destruction, they also act as professional antigen presenting 
cells.  T helper cells greatly impact the development and specialization of B cell responses 
and B cells conversely impact T-cell activation. Within this intricate relationship between 
both arms of immunity, cellular and humoral responses together determine the outcome 
of intracellular infection[12]. 
 
B cells forms a large part of bacterial induced  immune responses to infection; they are 
detected in large numbers within granuloma lesions, yet the role of B-cells in immune 
protection is not clear[12].  
Antibodies show properties to control infectious agents by preventing antigen entry and 
inhibiting replication, neutralizing toxins from pathogens and promoting antibody 
dependent cellular cytotoxicity, they lead to opsonization, trigger the complement 
cascade, Fcǲ receptor cross-linking  and promote cytokine release. B cells function as 
Antigen Presenting Cells, regulate T cell differentiation and are able to induce T cell 
responses against certain intracellular microbes. Even though antibodies interact with 
extracellular pathogens to control infection, M.tb have both intracellular and extracellular 
stages in the course of TB infection that would allow antibodies to play a role during the 
entrance to the respiratory tract in the host or when M.tb escapes from the phago-
lysosome in the macrophage. Yet researchers believe that M.tb usually resides within the 
vacuole. Thereafter antibody responses might allow production of effective 
immunoglobulin and passive immunization as potential defense in adaptive immune 
response. Intracellular pathogens like Clamydia species, Plasmodium, Cryptococcus 
neoformans and Schistosoma induce humoral and cellular mediated immune responses 
[13-15]. 
Experimental studies of M.tb are mainly based on murine models; pathologic progression 
of murine TB, or immune protection in murine models are ill-defined. This is also true for 
the biological role of antibody response against M.tb and M.tb (re) activation. The 
following  examples show the relationship between cell mediated immunity (CMI) and 
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humoral immunity: in B cell deficient mice, deficiency of IgM µ-chain results in three to 
eight fold counts of viable bacilli a compared with healthy  mice at 3-6 weeks post 
infection[16].  Other study showed that B cell deficient mice have exacerbated pathology 
and elevated numbers of pulmonary neutrophils [17] as wells as increased IL-10 
production in lungs along with increased susceptibility to M.tb infection. Certain 
monoclonal antibodies demonstrated effects in limiting extra pulmonary M.tb 
dissemination. This included increased survival of infected animals and granuloma 
formation in case when BCG was coated with IgG2 and IgG3 anti heparin-binding 
haemagglutinin adhesion (HBHA) mAbs [18]; the same was found to be true for intranasal 
monoclonal IgA installation, i.e. ĂŶƚŝɲ-crystalline in BALB/c [19]. Particularly M.tb antigens 
MPT83, Ag85A, Ag85B, HBHA and CFP-10/CFP-21 appear to induce protective antibodies 
[14]. 
 
Cellular immune response- Acquired immunity to M.tb relies on cell mediated immunity 
(CMI) that primarily target intracellular pathogens that reside in a vacuole within 
macrophages. Mycobacterial antigens are presented by and restricted to Major 
Histocompatibility Complex class II antigens.  The increase of CD4+ T cells correlates to 
protection against TB, they are capable to induce effector cells to control mycobacterial 
growth and dissemination in the host. Essentially CD4 T cells produce Th1 cytokines like 
IFN-΅, IL-2 and TNF-ɲthat play a critical role in controlling TB infection; particularly IFN-΅  
is important in controlling M.tb infection; it activates macrophages and induces the 
production of nitric oxide (NO) by nitric oxide synthase (NOS) which promotes killing of 
intracellular bacilli.  CD4 T cells interact via CD40 and CD40L on macrophages and dendritic 
cells leading to enhanced antigen presentation. 
CD8+ T cells participate in protection against TB associated with production of IFN-ɶĂŶĚ
subsequent activation of macrophage; IFN-ɶpromotes granzyme, perforine production.  
Antigen presentation to cytolytic T lymphocytes (CTLs) involve MHC class I molecules that 
can uptake the antigen from the cytosolic compartment, the endoplasmic reticulum.   
M.tb - infected macrophages undergo apoptosis and lead to the formation of vesicles 
containing mycobacterial antigens that can be processed by DCs presenting them in the 
context of MHC-II, MHC-I and CD1 [20-21].  
‘Unconventional T cells’ are ill-defined  in the context of protective immune responses of 
tuberculosis; these immune cells can also produce cytokines (IFN-ɶͿĂŶĚƉƌŽĚƵĐĞĐǇƚŽƚŽǆŝĐ
activity, similar to CD8 CTLs. CD1 can present specific mycobacterial lipids and glycolipid 
peptides to T cells (in part TCR gamma/delta T-cells).  CD1 molecules anchor short 
peptides and are structurally similar to MHC class I, yet the antigen binding groove is 
deeper and more hydrophobic than MHC I and II. Similarly ǲɷ T cells are not only limited 
to cytokine production or to cytolytic effector functions, but they can efficiently 
 
 11 
humoral immunity: in B cell deficient mice, deficiency of IgM µ-chain results in three to 
eight fold counts of viable bacilli a compared with healthy  mice at 3-6 weeks post 
infection[16].  Other study showed that B cell deficient mice have exacerbated pathology 
and elevated numbers of pulmonary neutrophils [17] as wells as increased IL-10 
production in lungs along with increased susceptibility to M.tb infection. Certain 
monoclonal antibodies demonstrated effects in limiting extra pulmonary M.tb 
dissemination. This included increased survival of infected animals and granuloma 
formation in case when BCG was coated with IgG2 and IgG3 anti heparin-binding 
haemagglutinin adhesion (HBHA) mAbs [18]; the same was found to be true for intranasal 
monoclonal IgA installation, i.e. ĂŶƚŝɲ-crystalline in BALB/c [19]. Particularly M.tb antigens 
MPT83, Ag85A, Ag85B, HBHA and CFP-10/CFP-21 appear to induce protective antibodies 
[14]. 
 
Cellular immune response- Acquired immunity to M.tb relies on cell mediated immunity 
(CMI) that primarily target intracellular pathogens that reside in a vacuole within 
macrophages. Mycobacterial antigens are presented by and restricted to Major 
Histocompatibility Complex class II antigens.  The increase of CD4+ T cells correlates to 
protection against TB, they are capable to induce effector cells to control mycobacterial 
growth and dissemination in the host. Essentially CD4 T cells produce Th1 cytokines like 
IFN-΅, IL-2 and TNF-ɲthat play a critical role in controlling TB infection; particularly IFN-΅  
is important in controlling M.tb infection; it activates macrophages and induces the 
production of nitric oxide (NO) by nitric oxide synthase (NOS) which promotes killing of 
intracellular bacilli.  CD4 T cells interact via CD40 and CD40L on macrophages and dendritic 
cells leading to enhanced antigen presentation. 
CD8+ T cells participate in protection against TB associated with production of IFN-ɶĂŶĚ
subsequent activation of macrophage; IFN-ɶpromotes granzyme, perforine production.  
Antigen presentation to cytolytic T lymphocytes (CTLs) involve MHC class I molecules that 
can uptake the antigen from the cytosolic compartment, the endoplasmic reticulum.   
M.tb - infected macrophages undergo apoptosis and lead to the formation of vesicles 
containing mycobacterial antigens that can be processed by DCs presenting them in the 
context of MHC-II, MHC-I and CD1 [20-21].  
‘Unconventional T cells’ are ill-defined  in the context of protective immune responses of 
tuberculosis; these immune cells can also produce cytokines (IFN-ɶͿĂŶĚƉƌŽĚƵĐĞĐǇƚŽƚŽǆŝĐ
activity, similar to CD8 CTLs. CD1 can present specific mycobacterial lipids and glycolipid 
peptides to T cells (in part TCR gamma/delta T-cells).  CD1 molecules anchor short 
peptides and are structurally similar to MHC class I, yet the antigen binding groove is 
deeper and more hydrophobic than MHC I and II. Similarly ǲɷ T cells are not only limited 
to cytokine production or to cytolytic effector functions, but they can efficiently 
 12 
themselves present antigens and recognize phosphorylated ligands. 
 
Interleukin 17-A 
IL-17 is a potent pro inflammatory cytokine secreted by activated T lymphocytes and may 
contribute to granulopoiesis. IL-17 is secreted as a disulfide-linked homodimeric 
glycoprotein with a molecular weight of 30-35 Kda. IL-17 is overexpressed in a number of 
several pathological conditions including inflammatory airway disease, transplant 
rejection, multiple sclerosis or rheumatoid arthritis [22]. 
During Mycobacterium bovis BCG infection, IL-17 is expressed during both the early innate 
and the adaptive immune response, In BCG infected animals,  ɶɷнdĐĞůůƐĂƌĞƚŚĞƉƌŝŵĂƌǇ
cellular source of IL-17, accounting for more than 60% of the IL-17 producing population. 
In turn, IL-17 contributes to acute neutrophil-mediated inflammation. In the absence of IL-
17, a significantly lower number of neutrophils are recruited into the bronchoalveolar 
lavage fluid due to the decreased activity of neutrophils contributing to cytokine and 
chemokine production. In a human study comparing M.tb infected patients with healthy 
donors, the proportion of IL-ϭϳƉƌŽĚƵĐŝŶŐɶɷ T cells decreased in patients with 
tuberculosis compared with healthy donors. Furthermore, the bacterial burden between T 
ĐĞůůƌĞĐĞƉƚŽƌɶɷŬŶŽĐŬŽƵƚs and wild type control mice did not differ significantly, yet 
granuloma structures were found to be less organized with a decreased composition of 
lymphocytes and monocytes after M.tb infection. Impaired granuloma formation is also 
observed in the lungs of IL-17 deficient mice infected with BCG, highlighting the 
importance of IL-17 in proper formation of tubercular granulomas [23]. 
 
2.3 QUIESCENT STATE AND GRANULOMA  
 
One of the existing hallmarks in tuberculosis is the equilibrium of the host immune 
response and the mycobacteria provided by specific structures that contain the M.tb in a 
dormant state. It is currently debated if this containment can be maintained during life 
time and which mechanism tilt the balance to a non-effective immune response. The 
granuloma formation is an organized aggregate of immune cells as a consequence of cell 
activation to contain M.tb therefore preventing M.tb dissemination and active disease. It 
also involves remodeling of the lung parenchyma. This mechanism consists in the 
activation of a cellular recruitment network mediated by cytokines that provide cell 
migration, adhesion and localization; ICAM-1 (intracellular adhesion molecule) and TNF-ɲ
for instance play a key role in this process. The core of the granuloma shows caseation,   
necrosis, restricted nutrition factors and a lack of oxygen where the M.tb is able to persist 
with limited metabolic functions. The infiltration of cells around the granuloma core are 
concentric layers of macrophages, epithelial cells, multinucleated Langerhans cells, 
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lymphocytes and a fibrotic outer layer. David and Ramakrishna (2009) refute the classical 
formation and function of granulomas and have shown in a study of zebra fish embryos 
infected with M. marinum that granulomas accelerate and increase the mycobacteria 
expansion; however this model seems to be different to the human natural infection and 
biology.  
Figure 3. Potential biomarkers of protection during tuberculosis infection. Different 
stages during pathogenesis help to differentiate cell compartments, pathways and 
peptides involved in replicating, non-replicating or quiescent mycobacteria 
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2.4 CELL WALL STRUCTURE AND IMMUNOGENICITY 
 
M.tb is different from other bacteria since it is surrounded by a complex cell envelope 
integrated by a cytoplasmic membrane and a cell wall; it represents a major virulence 
factor of M.tb, contributes to drug resistance and is responsible for M.tb survival under 
environmental stress. The cell wall consists in inner core of micolic acids, covalently 
attached lipids, carbohydrates and proteins intercepted in a matrix of peptidoglycans. 
Long fatty acids chains compound micolic acids characterized for cyclopropane rings and 
double bounds, they link to peptidoglycan via an arabinogalactan polymer of arabinose 
and galactose subunits. The long branch, up to 90 carbon units forming micolic acids, 
account for 30-40% of the cell envelope mass; their depletion, lost or mutagenesis 
correlates with alterations in membrane structure, permeability and mycobacterial 
survival. 
Several mycobacterial genes have been identified as virulence factors but biologically and 
clinically relevant key-genes and proteins for M.tb maintenance, persistence and survival 
of M.tb within macrophages, are still to be identified.  
In this sense, proteomics and genomics have opened an opportunity for studying 
morphology, physiology and evolution of M.tb. The capacity of the M.tb genome, 
characterized by 4,411,529 base pairs (bp) and 3,924 open reading frames [24], provides 
gene products capable of being expressed during different stages of the TB infection 
eliciting cellular and humoral responses. The functionality of these genes shows M.tb lipid 
metabolism, cell-wall processing, virulence and antigenic variation, yet there still remains 
a 33% of hypothetical and unknown proteins to be elucidated [25-26]. The selection and 
understanding of TB antigens is a challenging perspective to define targeted cellular and 
humoral immune responses.  
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3 CORRELATES OF PROTECTION, CHAPTER 3 
3.1 LIMITED EFFICACY OF BCG AND NEED OF EFFECTIVE VACCINE 
 
The immune protection against tuberculosis aims to eliminate rapidly M.tb, including live 
mycobacterial-based vaccines as strategies. Despite several designs and attempts for an 
effective vaccine, all those efforts have been partially successful. Bacille Calmette and 
Guerin (BCG) is a live vaccine from an attenuated strain of Mycobacterium bovis, yet there 
is not protection against adult pulmonary TB and it limits only the systemic forms of TB in 
newborns. Since its introduction in 1921, different BCG vaccine strains variances exists 
due to genetics modifications occurred during repeated subcultures in different countries, 
these differences may be associated with the different protective efficacy against TB. 
The particular BCG strain used worldwide depends of several factors such as logistics or 
cost, local production, or historical precedents. There is a range of global policies that 
regulates the use and age of BCG vaccination, doses and methodology for delivery. The 
BCG vaccination might affect the results in the Tuberculin skin test (TST) provoking cellular 
hyper-reactivity, this can be detrimental in immune-suppressed individuals.  Furthermore, 
BCG vaccination is not useful any longer for the population already infected by M.tb. 
Despite nearly a century of use, BCG remains controversial with known variations of BCG 
sub strains, vaccine efficacy, policies and practices around the world [27].  
  
 
3.2 BIOMARKERS OF PROTECTION AND NEW VACCINE CANDIDATES 
 
There is a still a need to develop novel vaccines against TB that can be used in sensitized 
individuals, both due to exposition to environmental mycobacteria or previous BCG 
vaccination, or in (M.tb) latently infected subjects. 
A biomarker of protection in the clinical context of vaccines and efficacy against disease is 
a “Feature that is objectively measured and evaluated as an indicator of a normal or 
pathological process of the response to an intervention” (Biomarkers definitions Working 
Groups, 2001). The lack of immune correlates of TB protection and the absence of 
biomarkers for vaccine candidates are challenges for vaccine development that need to be 
addressed.  
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individuals, both due to exposition to environmental mycobacteria or previous BCG 
vaccination, or in (M.tb) latently infected subjects. 
A biomarker of protection in the clinical context of vaccines and efficacy against disease is 
a “Feature that is objectively measured and evaluated as an indicator of a normal or 
pathological process of the response to an intervention” (Biomarkers definitions Working 
Groups, 2001). The lack of immune correlates of TB protection and the absence of 
biomarkers for vaccine candidates are challenges for vaccine development that need to be 
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Currently vaccine strategies include i) a pre-exposure vaccine for preventing disease and 
establish ‘better’ immune responses be improving the existing BCG i.e. recombinant rBCG, 
ii) a pre-exposure vaccine mounting a robust immune response before M.tb spreads in the 
host. iii) a post-exposure vaccine that prevents reactivation in a population with latent TB 
iv) a post-exposure vaccine that helps to prevent reactivation in high risk groups. 
Alternative strategies for TB vaccine also include antigens as potential boosters, currently 
in clinical trials are Ag85A, Ag85B, ESAT-6, CFP-10, TB10.4, Mtb72f, HBHA, which aim to 
prolong and strengthen the host immune response [28-29].  
 
 
3.3 HETEROLOGOUS IMMUNITY AND CROSS REACTIVITY 
 
Heterologous immunity is the term used to describe the phenomenon by which memory T 
cells that were generated during an earlier infection are reactivated in response to a 
second, unrelated infection or target.  Each history of past infections may be able to shape 
the memory T cell pool. Private T cell receptor specificities of these preexisting memory T 
cell population influence both disease severity and outcome of subsequent unrelated 
infections [30-31]. 
The nature of T cell recognition is degenerate,  a single T cell can often recognize more 
than a single epitope, one calculation suggesting as many as 106 peptide-MHC 
combinations [32]. CD8 T cells have been shown to be cross-reactive between two 
different epitopes from the same (viral) protein [33-34], between two proteins within the 
same virus [33, 35], between similar proteins of closely related viral pathogen [36-38], and 
between different proteins of unrelated viruses [39-40]. These cross-reactive epitopes 
may or may not have significant amino acid homology. Cross-reactive epitopes have also 
been shown between proteins of viruses and intracellular bacteria [41]. The mobilization 
of cross-reactive memory cells into a primary immune response can alter protective 
immunity, immunopathology, and the immune-dominance of subsequent T cell responses 
[36]. 
Welsh and Selin have broadly studied T-cell crossreactivity in infectious diseases 
suggesting that heterologous immunity can disrupt T cell memory pools, change pattern of 
T cell immune-dominance, lead to the selection of viral epitope-scape variants, alter the 
pathogenesis of viral infections, or contribute to variations in infectious diseases due to 
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the private specificity of T cell repertoires within individuals [42]. Epitope prediction and 
homology between sequences may allow identification of particular components for new 
vaccines and pathogenesis of tuberculosis. 
 
4 ABOUT THIS THESIS 
 
4.1 GENERAL AIM 
 
The aim of this project is to better understand immune responses against Mycobacterium 
tuberculosis by defining M.tb specific immune responses in individuals with active and 
latent M.tb infection in Honduras using cell-based immune assays and a panel of specific 
M.tb. target antigens 
 
4.2 SPECIFIC OBJECTIVES 
 
; To identify the immunological profile in individuals with active and latent tuberculosis 
using different M.tb targets. 
; Testing of novel M.tb targets useful for diagnosis and potential vaccine candidates. 
; Implementation of the Quantiferon test and introduction/application of the Whole 
blood assay (WBA) detecting M.tb antigen –directed immune responses (screening). 
; To characterize TB10.4 recognition in human and non-human primates (NHP) and to 
determine mimicry epitopes from environmental antigens in order to study cellular 
immune responses in TB and the role of repetitive antigen exposure. 
 
4.3 SUMMARY OF THE PROJECT 
Our research interest has being focused on ex vivo testing of potential tuberculosis vaccine 
candidates and M.tb antigens expressed at different stages of human TB, i.e. latent vs. 
clinically active TB.  Individuals with latent or active TB were longitudinally monitored.  The 
use of a broader panel of M.tb and MOTT (Mycobacterium other than tuberculosis) -
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associated antigens may aid to dissect the precise targets of CD4- and CD8-mediated 
immune responses in M.tb patients. Thus, a broad array of M.tb antigens may be helpful to 
dissect immune responses to i) replicating bacteria, ii) ‘quiescent’ bacteria, ii) antigens able 
to differentiate between M.tb, MOTT and BCG (e.g. CFP10, ESAT-6). Of particular interest 
were M.tb-antigens expressed by non-replicating mycobacteria (persistence) and with 
clinical latent tuberculosis (since there is a need for a fast diagnosis of latent TB).  Changes in 
both the magnitude of the response to some antigens and the nature of the immune 
response may allow us to better define the status of the TB infection. 
In this study, we selected a well-defined population with newly diagnosed (TB positive cases 
and) a non TB population (health care workers and people with other respiratory diseases) 
which allowed us to determine biologically relevant information regarding to the immune 
response associated with the different status of TB infection. The project included the 
implementation of immunological based tests: Quantiferon Assay and WBA-Whole Blood 
Assay, Microarray Technology) with the antigens ESAT-6 (differentiation between M.tb vs. 
BCG and MOTT), Ag85A/B and TB10.4 (activity). IFN-ɶǁĂƐĚĞƚĞƌŵŝŶĞĚŝŶƚŚĞƐƵƉĞƌŶĂƚĂŶƚƐ͘
Data was obtained and reviewed in association with clinical findings, results of the acid-fast 
staining, and isolation of viable bacteria. In a second set, the ‘classical M.tb antigens (ESAT-
6, Ag85A/B, TB10.4) were supplemented with an array of 13 M.tb peptide candidates and a 
set of 8 M.tb proteins to evaluate between replicating and non-replicating bacteria. 
Heparin-blood was ficolled and isolated PBMCs stored in liquid nitrogen to allow for the 
replication of experiments to further dissect cellular immune responses using intracellular 
cytokine staining (ICS).  
In order to get specific immune response patterns, the population has been subdivided 
according to TB and HIV status. Data were obtained and correlated with the traditional TB 
diagnosis tests (acid fast staining and Löwenstein Jensen culture) 
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Study project summary 
 M.tb Antigen testing Methodology Parameters Study Population 
     
Study I M.tb 15 mers long 
peptides n=13 
 
 
 
Whole Blood Assay 
Quantiferon Assay 
ELISA 
Mycobacteriology 
 
 
IFN-ɶ 
IL-17 
1.1 TB+HIV- Culture & 
AFS positive 
* M.tb protein antigens 
n=8 
1.2 TB-HIV- Control, 
other respiratory 
diseases 
* Classical M.tb peptides 
(n=3) & proteins (n=5) 
1.3 TB-HIV- Previous 
TB and exposed 
Health care workers 
 
Study II 
 
1. TB10.4 Epitope 
Mapping. P1-P21 
 
 
 
Whole Blood Assay 
Microarray 
Technology 
Luminex 
ELISA 
 
IFN-ɶ 
B cell reactivity 
Multiple cytokine 
& chemokines 
 
1.1 TB+,TB- subjects, 
NHP 
2. Mimicry Peptide and 
Cross reactivity. M1-M8 
2.1  TB+,TB- subjects 
  
 
4.3 MATERIALS AND METHODS 
 
WBA Whole Blood Assay, WBA 
We set up a T cell based assay (7 days) using diluted whole blood and specific TB antigens in 
order to measure T cell responses, cytokine production and cellular proliferation.  Central 
memory T cell responses critical for long term protection are usually gauged in this assay.  
The cell cultures were incubated for 7 days at 37°C/CO2 in duplicate wells; supplemented 
with RPMI/penicillin/streptomycin media in order to get supernatant containing 
lymphoblast and cytokine production in response to M.tb antigens. Results are provided by 
quantitative measurement of cytokines by ELISA.  
Recombinant / Synthetic Mycobacterium tuberculosis antigens 
TB bacterial antigens were provided by peptides, 15-mers long; Peptide pools were 
synthesized by JPT Peptide Technologies, Berlin, Germany at a final concentration of 
1mg/ml. Recombinant proteins were used at 5mg/ml. A mixture of Staphylococcal 
Enterotoxin A (SEA) and B (SEB), (SEA/SEB; 10ng/ml) (Sigma Aldrich, USA) and 
Phytohemagglutinin (PHA; 5µg/ml) both were used as a positive control and RPMI medium 
(RPMI 1640 W/Glutamax supplemented with 1% Hepes and 0.5% Penicillin-Streptomycin) 
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without any stimulation as negative control. Peptide pools and proteins are described in the 
table below. 
Gene locus RefSeq Antigen name 
                                                                   Peptides 
Rv0447c NP854118  (Pool 1) Probable cyclopropane Fatty acyl phospholipid synthase. 
ufaA1. (M.bovis)  
Rv2940c YP_976584 (Pool 2) Mycocerosic acid synthase. mas. (M.bovis) 
Rv3347c YP_177963 (Pool 3) PPE family proteins. PPE55. (M.tb) 
Rv2453c CAA16030  (Pool 4) Probable molybdopterin-guanine dinucleotide biosynthesis 
Protein A. mobA. (M.tb)  
Rv1886c CAB10044  (Pool 5) Antigen 85B. fbpB. 
Rv1690 CAB10947  (Pool 6) Probable lipoprotein. lprJ. (M.tb) 
Rv3019c CAA16104  (Pool 7) ESAT-6 like protein. esxR. (M.tb) 
Rv2957 CAB05419  (Pool 8) PGL/p-HBAD biosynthesis glycosiltransferase. MT3031. (M.tb) 
Rv1085c CAA17201  (Pool 9) UPF0073 membrane protein. MT1117. (M.tb) 
Rv0066c CAA16247 (Pool 10) Isocitrate dehydrogenase, NADP-dependent- icd2. (M.tb) 
Rv2958c CAB05418 (Pool 11) PGL/p-HBAD biosynthesis glycosiltransferase. MT3034. (M.tb) 
Rv2962c CAB05415 (Pool 12) PGL/p-HBAD biosynthesis rhamnosyl-transferase. MT3038. 
(M.tb) 
Rv0288 CAA17363 TB10.4 (pep pool). Low molecular weight protein antigen 7. 
esxH. ESAT-6 like protein. (M.tb) 
Rv3804c/1886 CAA17868/CAB10044 Ag85A/Ag85B. Fibronectin binding protein  -peptide pool- 
fbpA/fbpB 
Rv3875/3874 CAA56099/CAA17966 ESAT-6/CFP-10. Peptide complex EsxA/EsxB 
______________________________________________________________________________________ 
Proteins 
Rv3804c CAA17868 Ag85A. Secreted antigen 85A. Mycolyl transferase 85A. fbpA. 
Ag85 complex. (M.tb) 
Rv1886c CAB10044 Ag85B. Secreted antigen 85B. Mycolyl transferase 85B. fbpB. 
Ag85 complex. (M.tb) 
Rv3875 CAA56099  ESAT-6. 6 KDa early secretory antigenic target. esxA. (M.tb) 
Rv3874 CAA17966 CFP-10. 10 KDa culture filtrate antigen. esxB. (M.tb) 
Rv0754 CAE55319 PE_PGR11. PE-PGRS family protein. (M.tb) 
Rv0978c CAE55343 PE_PGR17. PE-PGRS family protein. (M.tb) 
Rv1917c CAE55440 PPE34. PPE family protein. (M.tb) 
Rv0288 CAA17363 TB10.4. Low molecular weight protein. (M.tb) 
 
IGRA- Interferon Gamma Release Assay, Quantiferon TB Gold in Tube  
We performed the assay in test tubes including a negative control (Nil tube), positive control 
(mitogen tube) and a tube with TB antigens (ESAT-6, CFP-10, TB7.7) incubating all at 37°C 
16-24 hours; after the incubation period, tubes were centrifuged and plasma collected to 
measure the amount of IFN-ɶďǇthe Enzyme Linked Immunosorbent Assay. Interpretation 
was done using specific software including an internal quality control and a standard curve. 
A positive result is considered if IFN-ɶin the antigen tube is clearly superior to the IFN-ɶEŝů
antigen in UI/ml (more than 2 standard deviations).  The mitogen tube is used to determine 
the positive results of each sample; a low stimulation of mitogen (<0.5UI/ml) indicate an 
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undetermined result when the blood sample presents a negative reaction. Individuals with 
Nil values greater than 8UI/ml are classed as “indetermined” because a 25% higher 
response to the TB antigens may be outside the assay measurement range; this may occur 
due to excessive levels of IFN-ɶŽƌ presence of heterophile antibodies or deviation of the 
procedure. A positive result for Quantiferon is when: TB antigen – Nil >/ 0.35 UI/ml , TB 
antigen – Nil >/ 25% of Nil UI/ml value , Nil </ 8UI/ml. The result is negative when the 
conditions mentioned above are not fulfilled. 
 
Microarray Peptide Technology 
Testing immune reactivity of TB antigens was performed by using a Microarray Peptide, a 
serum-antibody based test. The generation of binding patterns helps to identify antigenic 
epitopes and characterize vaccine targets, it is also valuable in monitoring immune 
responses in vaccine trials. The recognition of the antigen often depends of its conformation 
identifying immunoglobulin’s secreted by primed B cells [43].  
In our study, the antigen array is a glass slide coated with several thousand of peptides from 
M.tb antigens. These peptides are attached on a solid surface detecting the presence of 
equal number of antibody specificities. The adaptive immunity generates specific antigen 
receptor with a high level of affinity in response to a stimulus. The aim of antibody profiling 
is the determination of immunoglobulin’s secreted by primed B cells with target epitopes 
estimating effector functions triggered by the binding events.   
The serum reactivity of M.tb was studied using a glass array of 15 mers with overlapped 
peptides derived from M.tb protein. Serum was incubated with for 16 hours, after several  
washing steps,  a secondary antibody Cy5 was added which is conjugated to a fluorescent 
probe followed by washing steps and drying the slide. The correspondent activity is 
measured by fluorescence intensity using a wave length at 635nm in a digital scanner 
GenePix Pro 5.1 software (Axon Instruments) which provides raw data reflecting the 
antibody immune responses of each individual to defined peptide vaccines.  
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Luminex, Bioplex Assay 
 
This system of technology is based on the principle of flow cytometry to stream beads in 
single file past a pair of lasers. The Luminex immune-detection assay (Milliplex® MAP, 
Stockholm, Sweden) aims to analyze a large number of cytokines and chemokines based 
on color codes beads, called microspheres, read on a specialized analyzer. Within the 
Luminex compact analyzer, lasers excite the internal dyes that identify each microsphere 
particle, and also any reporter dye captured during the assay. 
Each microsphere has a unique spectral signature using different intensities of dyes 
reaching up to hundred tests in a single reaction. The microspheres are coated with 
specific capture antibodies in order to react with the analyte in our stimulated cell culture 
supernatant, together with standards and quality controls.  
The stimulated supernatant was tested in order to determine multi-analytes in a low 
amount of sample. After incubation and washing steps, biotinylated detection antibody is 
added and followed by a conjugate of Streptavidin-Phycoerythrin. The beads are washed 
and re-suspended in a sheat fluid to prior analysis in Luminex instruments (Luminex 200™) 
using two different lasers of light source exiting the internal beads and PE conjugate or 
any reported dye captured during the assay measuring Median Fluorescent Intensity (MFI) 
and calculating cytokine and chemokines concentrations (pg/ml) with curve-fitting 
method. 
 
IFN-ɶĂŶĚ/>-17 ELISA 
 
During our study we performed the IFN-ɶ ĂŶĚ />-17A; ELISA (Eli-pair DIACLONE, Biosite, 
Stockholm, Sweden). The sample, supernatants from stimulated immune cells, were 
tested by ELISA. The basic principle of ELISA is to use an enzyme to detect the covalently 
linked binding of antigen-antibody. The enzyme converts a colorless substrate 
(chromogen) to a colored product indicating the binding of antigen-antibody. In brief, 
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Luminex, Bioplex Assay 
 
This system of technology is based on the principle of flow cytometry to stream beads in 
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detection antibody for 2 hours at room temperature (RT). For IL-17, samples were 
incubated with coated antibody during two hours, washed three times and incubated with 
the detection antibody for 1 hour at room temperature. In both assays, after 3 washing 
steps, the plates were further incubated at RT with HRP-Streptavidin for 20 minutes. After 
washing step, TMB was added into the wells and plates were further incubated for 10-15 
minutes in the dark. The reaction was stopped by adding 1M H2SO4 each well and the 
plates were read for absorbance at 450nm. A linear standard curve was drawn in order to 
obtain the unknown cytokine concentration where O.D. values were extrapolated with the 
given standard curve. The values were multiplied by their corresponding dilution factor 
and the concentration was expressed in pg/ml. The detection range for INF-ɶǁĂƐϰϬϬ-7 
pg/ml and for IL-17 100-3.1 pg/ml. 
 
Cell Separation and Cryopreservation 
 
During the developing of the study we collect peripheral blood mononuclear cells (PBMC) 
in order to get access to more detailed information. We implement the use of Vacutainer 
cell preparation tubes (CPT) with sodium heparin for peripheral blood collection and 
further lymphocyte purification using a rapid centrifugation procedure and assessment of 
the cellular viability. The cell separation medium is comprised of polyester gel and a 
density gradient liquid. 
Samples were mixed properly by inversion prior to centrifugation; tubes were centrifuged 
during 15 minutes at 2800rpm at room temperature. After this step, mononuclear cells 
and platelets will be in the layer just under the plasma layer; the cells are suspended into 
the plasma and the entire content is transferred to 50 ml tubes, pooling the 2-3 CPT tubes 
of each patient and centrifuged during 10 minutes at 1700rpm and the plasma is 
separated and frozen at -80C freezer. The cell pellet is re-suspended and rinsed with PBS 
1ml and then approximately the same blood volume from start and centrifuge the tube for 
10 minutes at 1500 rpm and discard the supernatant; the cells are suspended in R10 
medium and taking a cell suspension of 100-200 µl for cell counting in a Neubauer 
Chamber. Further we record the total cell counting and viable cells. A final centrifugation 
step is performed 1250rpm during 10 minutes. The cell pellet were re-suspended and 
preserved with freezing medium 10% DMSO in RPMI-FCS20% into cryovials (1x106 
cells/ml), kept in a freezing device (prefilled with isopropanol) at -80°C during 12-24 hours 
to further transfer to liquid nitrogen. 
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Löwenstein Jensen Culture 
 
Bacteriology isolation, culture and identification of sputum samples were performed by 
using Löwenstein Jensen solid media and decontamination-Petroff methodology. 
The nutrients provided by monopotassium phosphate, magnesium sulphate, magnesium 
citrate, asparagine, potato flour and malachite green as inhibitor of accompanied flora; as 
well as an aggregate of glycerin to stimulate the growth of M.tb.  
The inoculums is performed in duplicate above the surface of the media, incubating them 
up to eight weeks observing and reporting weekly the colonial morphology, pigments 
producing or contaminations. Positive cultures are further identified with biochemical test 
of catalase production, niacin and reduction of nitrates to nitrites.    
 
 
 
4.5 SUMMARY OF RESULTS AND DISCUSSION 
 
STUDY I 
Increased IFN-ɶƉƌŽĚƵĐƚŝŽŶƚŽD͘ƚďĂŶƚŝŐĞŶƐŝŶďůŽŽĚĨƌŽŵŚĞĂůƚŚĐĂƌĞǁorkers exposed to 
M.tb as compared to TB patients 
We analyzed and identified in blood from 148 individuals a significant difference in IFN-ɶ
production in response to peptides Rv2958c, Rv2962c, Rv3347c, Rv3804c, and Rv1886c 
(protein):  between groups 1 (TB+) and 3 (health care workers); the antigens Rv2958c and 
Rv2962c were differentially recognized between group 2 (non-TB pulmonary diseases) and 3 
(health care workers). Immune cells from individuals in group 2 (TB-other respiratory 
diseases) and group 3 (exposed to TB, no clinical TB uninfected) produced significantly 
higher levels of IFN-ɶ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ ƐƚŝŵƵůĂƚŝŽŶǁŝƚŚZǀϭϴϴϲĐ ;ŐϴϱͿZǀϮϵϱϴĐ ;ŐůǇĐŽƐǇů-
transferase) and Rv2962c (pHBAD biosynthesis rhamnosyl-transferase). The recombinant 
protein antigens Rv3804c (Ag85A) and Rv3347c (PPE family member) induced the strongest 
IFN-ɶƉroduction in blood from M.tb exposed individuals as compared to TB + individuals. 
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A different M.tb target recognition pattern defined by IL-17 production 
We selected therefore 14 M.tb antigens for further analysis and tested IL-17 production in 
response to the antigens Rv0447, Rv1886c, Rv3019c, Rv2957, Rv2958c, Rv2962c (peptides) 
and the recombinant proteins Rv3804c, Rv1886c, Rv3874, Rv3875, Rv0288, Rv0754, 
Rv0978a and Rv1917. We were able to demonstrate significantly different IL-17 production 
in response to Rv1886c (Ag85B) in individuals from group 2 (non TB, other respiratory 
disease) and 3 (health care workers, exposed to TB). Immune cells from individuals in group 
2 and group 3 produced more IL-17 in response to Rv0978c (PPE family member), Rv0288 
(TB10.4) and Rv1917c (PPE family member). The highest IL-17 production was identified in 
blood from exposed individuals directed against the antigens listed above. 
 
Analysis between QFT-GIT and bacteriology 
We analyzed the cytokine responses in blood from individuals stratified by the QFT-GIT 
based on the acid fast stain result, culture positivity and previous history of TB). Immune 
cells from individuals with AFS + M.tb + culture showed decreased IFN-ɶƌĞƐƉŽŶƐĞƐƚŽƚŚĞ
positive (SEA/SEB) controls. ESAT-6 and CFP-10 immune reactivity was significantly higher in 
blood from individuals with AFS- and negative culture results– yet with a positive QFT-GIT 
for IFN-ɶ ƉƌŽĚƵĐƚŝŽŶ ;ĂŶĚ ĨŽƌ />-17 production in response to Rv3874, CFP10). Significant 
differences concerning cytokine response patterns could be identified in blood from 
patients with TB (AFS+, QFTGIT+ and culture+) versus blood from health care workers in 
response to Rv3804c (Ag85A, IFN-ɶƉ= 0.009 as well as for IL-17, p = 0.019) and Rv2962 
(pHBAD, rhamnosyl-transferase, p = 0.042 for IL-17 production). 
 
Discussion 
Anti-M.tb directed immune responses may be associated with immune-protection, yet also 
with immune-pathology, as shown for IL-17-driven cellular immune responses. IL-17 – 
associated immune responses can be protective or harmful in TB and may lead to lung 
tissue damage along with massive inflammation and influx of neutrophils. We were able to 
show that IFN-ɶŵĞĚŝĂƚĞĚƌĞƐƉŽŶƐĞƐƐŚŽǁĞĚƐƚƌŽŶŐĐĞůůƵůĂƌƌĞĐŽŐŶŝƚŝŽŶŽĨZǀϭϴϴϲĐ;ŐϴϱͿ͕
Rv3804c (Ag85A), Rv2958c, Rv2962c (enzymes associated with lipid-alteration) and Rv3347 
(PPE family member) in blood from individuals who have been exposed to M.tb, yet are 
clinically healthy.  
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Of interest is the quite different cellular reactivity concerning M.tb target pattern 
recognitions if IFN-ɶ ĂŶĚ />-17 are analyzed. Ag85B (Rv1886c) showed a similar trend 
concerning T-cell recognition, both for IFN-ɶĂŶĚ/>-17 production. Yet the antigen Rv0288 
(TB10.4) and two PPE family members (Rv0978c, Rv1917c) exhibited only statistical 
differences in IL-17 responses, yet not concerning the capacity to induce IFN-ɶƉƌŽĚƵĐƚŝŽŶ͘
Vice versa, the PPE family member Rv3347c, the enzymes Rv2958c (glycosyl-transferase) 
and Rv2962 (rhamnosyl-transferase) showed only differences in IFN-ɶƉƌŽĚƵĐƚŝŽŶďĞƚǁĞĞŶ
the populations (groups 1, TB + and 3, health care workers).  
Several explanations may apply for the differential recognition patterns defined by IFN-ɶ
and IL-17 production: Rv2958c and Rv2962 were tested as overlapping peptides; some 
peptides may be degraded and therefore not efficiently processed and presented to T-cells; 
the antigen processing and presentation of peptides may be different as compared to 
recombinant proteins. IL-17 production may require the intact protein structure and 
subsequent cellular processing and presentation. Other cellular mechanism may be 
important to initiate IL-17 production, i.e. the priming and activation of antigen presenting 
cells which will subsequently present the recombinant target protein to antigen-specific T-
cells.  
Of interest is the strong recognition, defined by IL-17 production, of TB10.4 (Rv0288c) and 
Ag85B (Rv1886c), two components of several TB vaccine candidates, in blood from healthy 
TB- exposed individuals. The strong TB10.4 recognition in blood from healthy individuals 
appears to be in contrast to the study of Sutherland and coworkers who reported a 
significant difference in IFN-ɶƉƌŽĚƵĐƚŝŽŶ͕ǇĞƚŶŽƚ/>-17 production, by comparing cytokine 
responses in blood from TB + cases (West Africa) and a TST- control cohort [67]. Several 
reasons may account for these differences, i.e. a different exposure history of the test 
population to M.tb and/or environmental mycobacteria and environmental pathogens and 
subsequent expansion of IL-17+ producing immune cells. Future studies may therefore need 
to dissect the role of the cell source of IL-17 production in response to M.tb targets and 
require the stratification of immune response analysis based on the distribution of immune 
cells subsets (T-ĐĞůůƐ͕E<͕E<d͕dZɶɷ+ T-cells) in the test samples. 
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STUDY II 
Dominant TB10.4 directed recognition of AWQAQWNQAMEDLVR in BCG-primed non-
human primates.    
Blood from NHPs were tested for detailed TB10.4 epitope recognition after the boost with 
rAD35, which followed the prime (BCG1331 or AFRO-1).  3 NHPs were not immunized and 
served as controls to gauge TB10.4 directed immune responses.   T-cell responses directed 
against a single peptide (TB10.4 P1453-67 AWQAQWNQAMEDLVR) were identified by IFN-ɶ
production in the BCG and rBCG group. We could not differentiate whether the dominant 
recognition of peptide P1453-67 was due to the prime or associated with the rAd35 boost. 
The fact that T-cells from NHPs, who were not BCG/AFRO-1 primed, yet only received the 
rAd35 boost, recognized the peptide P1453-67, suggests that the dominant response towards 
the epitope P1453-67 was associated with the boost. T-cells from non-vaccinated animals did 
not react to TB10.4 peptides. PBMCs from 5/24 animals did not exhibit recognition to any of 
the peptides. PBMCs from 1/24 animals exhibited not only reactivity to peptide P14, yet also 
to an additional peptide P20. PBMCs from 3/3 animals who had not been vaccinated 
showed IFN-ɶ ƉƌŽĚƵĐƚŝŽŶ ĂĨƚĞƌ ƚŚĞ M.tb challenge directed against the P14, 1/3 NHPs 
reacted to P1 and 1/3 to P6. In summary, BCG vaccination resulted in strong recognition of 
peptide P14 and this pattern did not appear to change after M.tb challenge.   
     
Humoral and cellular TB10.4 epitope mapping in TB+ and TB-exposed individuals.   
 
TB10.4 protein for immune-reactivity was tested using 21 synthetic overlapping peptides. 
In 23 HIV-negative subjects (TB+, n=7 and TB-, n=16). Both TB+ and TB- negative groups 
show a similar pattern recognition pattern based on IFN-ɶ ƉƌŽĚƵĐƚŝŽŶ͕ ǁŝƚŚ Ă ĚŝǀĞƌƐĞ
recognition of the TB10.4 protein. PBMCs from 4/7 subjects in the TB+ group exhibited 
recognition of peptides (P) P6, P11, P14 and P20. The strongest IFN-ɶproduction could be 
observed to P10, P2 and P11 (191, 110 and 109 pg/ml) respectively. Within the TB- group, 
recognition of peptides P1, P2 and P10 were shared among 7/16 individuals. T-cells from 
4/16 subjects did not produce IFN-ɶƚŽĂŶǇŽĨƚŚĞϮϭdϭϬ͘ϰ candidate test peptides.  
Next, we tested the TB10.4 protein for immune-reactivity using 21 synthetic overlapping 
peptides in 15 HIV-negative subjects (TB+, n=7 and TB-, n=8). The corresponding serums 
from the same individuals were tested for IgG recognition using peptide microarray 
technology.  This pattern was different as compared to the recognition of peptides P 2, 3, 
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11, 12, 15 in the TB+, as well as in the TB- group defined by IFN- ɶ production. Anti - 
peptide AWQAQWNQAMEDLVR reactivity was detected in a single serum sample. Since the 
peptide TB10.4 AWQAQWNQAMEDLVR was strongly recognized in NHPs after BCG and M.tb 
challenge, as well as in blood from patients with TB, we tested closely related peptides from other 
species, labeled as M1-M8. Blood from 4/7 individuals of the TB+ group and 8/16 subjects from 
TB- group did not respond to any of the variant, yet to the wild-type peptide. The report shows T-
cell responses within the TB positive group defined by IFN-ɶ production (between 8-60 pg/ml) with 
diverse recognition pattern including peptides from S. cerevisiae (M2) and to R. lactaris (M7). 50% 
of TB- individuals (TB-exposed individuals) showed a response to the 9mer peptide from TB10.4 
(M8) followed by reactivity to a peptide from S. cerevisiae (M2) and to A. fumigatus (M4).  
We tested additional cytokines (Th1/Th2) in blood from 4 TB+ patients and 4 TB-contacts 
who showed IFN-ɶ ƉƌŽĚƵĐƚŝŽŶ ƚŽǁĂƌĚƐ tYYtEYD>sZ͘ ŝƐƚŝŶĐƚ ĐǇƚŽŬŝŶĞ
production could be observed to the 9mer peptide from TB10.4 (M8) as well as to a peptide 
from S. cerevisiae (M2) and A. fumigatus ;DϰͿ͕ ĚĞĨŝŶĞĚ ďǇ dE&ɲ͕ /&E-ɶ ĂŶĚ 'D-CSF 
production. We could also observe IL-4 and IL-10 responses to variant peptides from S. 
cerevisiae (M2) and A. fumigatus (M4), as well as the 9mer peptide from TB10.4  
Discussion 
In this study we have investigated the cellular recognition pattern in response to targets 
from unrelated organisms that may skew the host immune response to TB10.4. Of interest 
is the consistent cellular immune response in PBMCs from NHPs to the TB10.4 peptide 
P1453-67 (AWQAQWNQAMEDLVR) as a response to result of BCG vaccination or the 
Adenoviral-TB10.4 boost. We identified in this report the peptide P1141-55 
SAWQGDTGITYQAWQ to be frequently recognized in PBMCs from TB patients. PBMCs from 
M.tb – negative individuals recognized the peptide P25-19   (MYNYPAMLGHAGDMA) which 
has reported to be frequently recognized in patients with TB or individuals after BCG 
vaccination; an epitope which has reported to contain a dominant CD8+ T-cell epitope in 
murine M.tb infection that is able to induce cytotoxic T-cell responses. The differences in the 
cellular TB10.4 immune recognition patterns between NHPs and TB+ patients may be due to 
inherent genetic differences (e.g. MHC restriction, TCR repertoire),  yet may also point to 
environmental factors; the ‘clean’ environment of M.tb infected (outbred) NHPs;  in contrast 
to humans, NHPs may favor a focused anti-TB10.4 directed immune response.  
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PBMCS from individuals from Honduras frequently recognized the epitope 
SAWQGDTGITYQAWQ. Several environmental and / or genetic factors could account for 
these differences. Exposure to microorganisms may generate T cell cross-reactivity. Shared 
amino acid sequences of unrelated pathogens could be the target of memory T cells and 
shape the encounter with the nominal TB10.4 target antigen in course of M.tb exposure or 
BCG vaccination. Further studies may have to address whether cytokine production in 
PBMCs from patients with TB is indeed related to TCRs that recognize structurally similar 
peptide species from different bacterial or fungal species and whether this T-cell reactivity is 
biologically and clinically relevant in the development of anti-M.tb directed immune 
responses.  
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